The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Therapies in Parkinsonʼs disease
Abstract
PURPOSE OF REVIEW: This review examines currently available therapeutic strategies for Parkinson's disease, emphasizing evidence-based data as well as a patient-centered approach to the treatment of motor and nonmotor symptoms. RECENT FINDINGS: Although clinical trials of disease-modifying approaches have been thus far disappointing, steady advances are being made in the symptomatic treatment of Parkinson's disease. In this review, we focus on recent studies with monoamine oxidase type B inhibitors (selegiline and rasagiline), coenzyme Q10, creatine, and exercise in early Parkinson's disease. We also discuss the relative merits and disadvantages of delaying the initiation of levodopa therapy, the role of dopamine agonists, particularly ropinirole and pramipexole, and management of motor and behavioral complications, such as fluctuations, dyskinesias and impulse-control disorders. Novel formulations and delivery approaches for conventional and new drugs are also discussed. Finally, we review recent studies of surgical treatments of Parkinson's disease, such as deep brain stimulation. SUMMARY: Numerous clinical trials have provided evidence that health-related quality of life can be substantially improved with early diagnosis and institution of exercise and other physical measures, appropriate timing of dopaminergic therapy, and strategies to delay and treat levodopa-related motor complications and nonmotor Parkinson's disease-related symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical progression in Parkinson disease and the neurobiology of axons
Cheng, H., Ulane, C. M., & Burke, R. E. (2010) · Annals of Neurology · doi:10.1002/ana.21995 · Cited by 1,012
Tai chi and postural stability in patients with Parkinson's disease
Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., Maddalozzo, G., & Batya, S. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107911 · Cited by 890
Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study
Aarsland, D., Larsen, J. P., Tandberg, E., & Laake, K. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb06891.x · Cited by 811
Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders
Jucker, M., & Walker, L. C. (2011) · Annals of Neurology · doi:10.1002/ana.22615 · Cited by 622
Does vigorous exercise have a neuroprotective effect in Parkinson disease?
Ahlskog, J. E. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab66 · Cited by 463
Physical activities and future risk of Parkinson disease
Xu, Q., Park, Y., Huang, X., Hollenbeck, A., Blair, A., Schatzkin, A., & Chen, H. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea1597 · Cited by 328
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
Weintraub, D., Mavandadi, S., Mamikonyan, E., Siderowf, A. D., Duda, J. E., Hurtig, H. I., Colcher, A., Horn, S. S., Nazem, S., Ten Have, T. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ebdd79 · Cited by 255
Randomized, double‐blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S., & Perlmutter, D. (2009) · Movement Disorders · doi:10.1002/mds.22401 · Cited by 143
Excessive Daytime Sleepiness in Patients with Parkinsonʼs Disease
Knie, B., Mitra, M. T., Logishetty, K., & Chaudhuri, K. R. (2011) · CNS Drugs · doi:10.2165/11539720-000000000-00000 · Cited by 132
Cited by
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Self-citationSignaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
Cabezas, R., Ãvila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., GarcÃa-Segura, L. M., Jurado Coronel, J. C., Capani, F., Cardona-Gomez, G. P., & Barreto, G. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00211 · Cited by 449
How to make a midbrain dopaminergic neuron
Arenas, E., Denham, M., & Villaescusa, J. C. (2015) · Development · doi:10.1242/dev.097394 · Cited by 308
Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports · doi:10.1038/srep04874 · Cited by 264
Metadata
- Authors
- Jankovic, J., & Poewe, W.
- Venue
- Current Opinion in Neurology
- Published
- 2012-08
- Volume
- 25
- Issue
- 4
- Pages
- 433-447
- ISSN
- 1350-7540 (ISSN-L)
- OpenAlex
- W1982189761
- Cited by
- 213
- References
- 9
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapies in Parkinsonʼs disease. https://app.cochat.ai/papers/10.1097/wco.0b013e3283542fc2
- The paper
- Jankovic, J., & Poewe, W. (2012). Therapies in Parkinsonʼs disease. Current Opinion in Neurology. https://doi.org/10.1097/wco.0b013e3283542fc2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.